HighRes at SLAS2021

SLAS2021

 

Tuesday, January 26, 2021  •  8:00 AM – 8:30 AM (EST)

Accelerating drug discovery using label-free MALDI-TOF mass spectrometry in uHTS

Speaker:  Fleur Kleinpenning, PhD
Scientist, Pivot Park Screening Centre, Oss, Gelderland, NetherlandsModerator:  Steven Van Helden, PhD
Chief Technology Officer, Pivot Park Screening Centre, Oss, Noord-Brabant, NetherlandsMass spectrometry (MS) is a label-free analytical technique which enables direct quantification of molecules relevant to (patho) physiology, but the low throughput of MS used to be a bottleneck in using this technique for (ultra) high-throughput screening (uHTS). Read the full description.
Register Today!
Tuesday, January 26, 2021  •  8:30 AM – 9:00 AM (EST)

Pipelines, Databases, Workflows—Making Phenotypic Data FAIR in a Single Facility and a Global Resource

Speaker:  Jason Swedlow, PhD
Professor, University of Dundee, DUNDEE, Scotland, United KingdomTh UK National Phenotypic Screening Centre (NPSC) provides phenotypic screening services using advanced cellular models for academic and commercial partners based around the UK and Europe. Assays include quantitative live cell assays for sperm motility, bronchoepithelial damage responses, inflammatory responses in skin, and T cell exhaustion, to name a few. All these assays produce large heterogeneous data collections that combine imaging data, and chemical and analytic metadata. The scale and heterogeneity of these data, and the fact that most critical data is stored in proprietary file formats, present acute informatics challenges. To store, process, share, analyse and publish these data, we employ tools from the Open Microscopy Environment an open-source software consortium that builds data management and access platforms. Read the full description.

Register Today!

Wednesday, January 27, 2021  •  7:00 PM – 7:30 PM (EST)

Functional immune mapping and drug discovery with AI-enabled, image-based cellular phenomics

Speaker:  Michael F. Cuccarese, PhD
Senior scientist, Recursion, Salt Lake City, Utah, United States

Development of accurate disease models and discovery of immune-modulating drugs is challenged by the immune system’s highly interconnected and context-dependent nature. We developed an automated platform for treatment of hundreds of immune perturbations in primary, immune-relevant cell types for use in the identification of dose-dependent, high-dimensional relationships at scale. Read the full description.

Register Today!

 

 

Request Info